Allegiance Financial Group Advisory Services LLC Invests $228,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Allegiance Financial Group Advisory Services LLC acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, HoldingsChannel reports. The fund acquired 969 shares of the biopharmaceutical company’s stock, valued at approximately $228,000.

Other institutional investors also recently modified their holdings of the company. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $61,160,000. Strategic Financial Concepts LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth $41,529,000. Los Angeles Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after purchasing an additional 8,462 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in shares of Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after purchasing an additional 2,285 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This trade represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,986 shares of company stock worth $20,397,849. Insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

ALNY has been the topic of several analyst reports. Chardan Capital reissued a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday. HC Wainwright upped their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Monday. StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Finally, Barclays upped their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $304.26.

Alnylam Pharmaceuticals Trading Down 0.5 %

ALNY opened at $243.86 on Thursday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The firm has a market capitalization of $31.57 billion, a PE ratio of -112.38 and a beta of 0.35. The company’s 50-day moving average is $254.33 and its 200 day moving average is $262.59.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.